Fig. 5.

Differential expression of TNFSF4 in B-ALLs and its effect on blinatumomab mediated cytotoxicity. a Violin plot of relative TNFSF4 expression in RS4;11 and SUP-B15 cells based on scRNA-Seq data. b Relative expression of TNFSF4 in RS4;11 and SUP-B15 cells as measured by qPCR. GAPDH was the input control. The experiment was conducted in three independent replicates. *P < 0.05; **P < 0.01; ***P < 0.001; Student’s t-test. c The combined density distribution curve of the relative expression of TNFSF4 (probe set id: 207426_s_at) in 576 patients with B-ALL from Microarray Innovations in LEukemia study (GEO accession: GSE13204) using of 2-component Gaussian mixture model. The black solid curve represents 2-component Gaussian mixture model fitting. Dashed curves represents the 2-component distribution in the mixture model (blue: low expression, red: high expression). The boxplot shows the expression distribution of TNFSF4 in the two groups. *P < 0.05; **P < 0.01; ***P < 0.001; Student’s t-test. d Specific lysis of SUP-B15 cells after treatment with 0.1 ng/mL blinatumomab and recombinant human TNFSF4 proteins. The experiment was conducted in three independent replicates. *P < 0.05; **P < 0.01; ***P < 0.001; Student’s t-test